GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » OncoCyte Corp (STU:7OC0) » Definitions » Operating Cash Flow per Share

OncoCyte (STU:7OC0) Operating Cash Flow per Share : €-3.06 (TTM As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is OncoCyte Operating Cash Flow per Share?

OncoCyte's operating cash flow per share for the three months ended in Dec. 2023 was €-0.51. OncoCyte's operating cash flow per share for the trailing twelve months (TTM) ended in Dec. 2023 was €-3.06.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 27.30% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 9.00% per year. During the past 10 years, the average Operating Cash Flow per Share Growth Rate was -7.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for OncoCyte's Operating Cash Flow per Share or its related term are showing as below:

STU:7OC0' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -37.4   Med: -10.1   Max: 27.3
Current: 27.3

During the past 11 years, OncoCyte's highest 3-Year average Operating Cash Flow per Share Growth Rate was 27.30% per year. The lowest was -37.40% per year. And the median was -10.10% per year.

STU:7OC0's 3-Year OCF Growth Rate is ranked better than
79.43% of 175 companies
in the Medical Diagnostics & Research industry
Industry Median: 2.1 vs STU:7OC0: 27.30

OncoCyte Operating Cash Flow per Share Historical Data

The historical data trend for OncoCyte's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoCyte Operating Cash Flow per Share Chart

OncoCyte Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Cash Flow per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -6.92 -6.52 -7.15 -7.77 -2.80

OncoCyte Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Operating Cash Flow per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.53 -1.52 -0.78 -0.26 -0.51

Competitive Comparison of OncoCyte's Operating Cash Flow per Share

For the Diagnostics & Research subindustry, OncoCyte's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OncoCyte's Price-to-Operating-Cash-Flow Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, OncoCyte's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where OncoCyte's Price-to-Operating-Cash-Flow falls into.



OncoCyte Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

OncoCyte's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (A: Dec. 2023 )=Cash Flow from Operations (A: Dec. 2023 )/Shares Outstanding (Diluted Average) (A: Dec. 2023 )
=-21.389/7.651
=-2.80

OncoCyte's Operating Cash Flow per Share for the quarter that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (Q: Dec. 2023 )=Cash Flow from Operations (Q: Dec. 2023 )/Shares Outstanding (Diluted Average) (Q: Dec. 2023 )
=-4.183/8.266
=-0.51

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-3.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


OncoCyte Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of OncoCyte's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


OncoCyte (STU:7OC0) Business Description

Traded in Other Exchanges
Address
15 Cushing, Irvine, CA, USA, 92618
OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers. Geographically operation of the group is carried through the United States.

OncoCyte (STU:7OC0) Headlines

No Headlines